Skip to main content

Table 4 Progression-free survival and overall survival of cisplatin/carboplatin, pemetrexed with or without bevacizumab in patients with nonsquamous non-small cell lung cancer

From: Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Study Phase Induction therapy Maintenance therapy PFS (months) OS (months)
Scagliotti, et al. [5] 3 CDDP + PEM 5.3 11.8
PARAMOUNT [6] 3 CDDP + PEM PEM 6.9
AVAPEARL [7] 3 CDDP + PEM + BEV PEM + BEV 10.2 NR
PointBreak [23] 3 CBDCA + PEM + BEV PEM + BEV 8.6 17.7
PRONOUNCE [12] 3 CBDCA + PEM PEM 4.44 10.5
MAP (The current study) 2 CDDP + PEM + BEV PEM + BEV 10.8 48.0
  1. PFS progression-free survival, OS overall survival, CDDP cisplatin, PEM pemetrexed, BEV bevacizumab, CBDCA carboplatin, NR not reached